Another example is SCCOHT, previously described as immune-high tumors as opposed to SMARCA4-UT.26,27 Like other mutations or deficiencies, tumor cell of origin may change the driver mutation pathogenesis and clinical outcomes. The gene discussed is SMARCA4; the disease is neoplasm.